Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of ...
The State14d
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected ...
Kansas City Star14d
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably ...
Fort Worth Star-Telegram14d
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably ...